This announcement serves to conclude agreements with pharmaceutical companies within the meaning of section 130a (8) sentence 1 SGB V. The invitation to participate is only addressed to pharmaceutical companies or groups of employees of pharmaceutical companies within the meaning of section 4 (18) of the Medicinal Products Act. It is not an open procedure according to § 15 VgV i. V. m. Section 119 (3) GWB, but to publish the invitation to conclude / join / to discount contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the discount. Contractual partners can become an unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the Medicines Act.

The purpose of this announcement is to conclude agreements on the active substance "Tacrolimus (ATC code: L04AD02) pharmaceutical form: HKP" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, Fifth Book (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "clonazepam (ATC code: N03AE01)" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active substance "desogestrel (ATC code: G03AC09)" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "dexamethasone, neomycin, polymyxin B (ATC code: S01CA01) pharmaceutical form: ATR" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Book V (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active substance "Iloprost (ATC code: B01AC11) pharmaceutical form: LOV" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Imatinib (ATC code: L01EA01)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, Fifth Book (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "metamizole (ATC code: N02BB02) dosage form: ILO, AMP" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "metamizole (ATC code: N02BB02) dosage form: suppositories" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Fifth Book (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "mesalazine (ATC code: A07EC02) pharmaceutical form: RSU, KLI, SUS" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active substance "miglustat (ATC code: A16AX06)" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, Fifth Book (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

This announcement serves to conclude agreements on the active ingredient "Sevelamer hydrochloride (ATC code: V03AE02)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements). According to Section 130a Paragraph 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 Paragraph 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to Conclusion / joining of / to discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under section IV.1.1) is only due to the system of this form. Contractual partners can have an unlimited number of pharmaceutical companies or associations of pharmaceutical companies in the According to § 4 paragraph 18 medicinal product elgesetz (AMG). The information under II.2.5) is due to the systematics of this publication form. The conclusion of a contract or joining takes place by either completing the required self-declarations or evidence as well as the contract or contracts:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Tacrolimus (ATC code: L04AD02) pharmaceutical form: REK" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "triamcinolone acetonide (ATC code: D07AB09) pharmaceutical form: SAL" with pharmaceutical companies within the meaning of § 130a sec. 8 sentence 1 of the Social Code, Fifth Book (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "vilanterol, umeclidinium bromide (ATC code: R03AL03)" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of Book V of the Social Code (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active substance "zolmitriptan (ATC code: N02CC03) dosage form: NAS, EDP " with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Tacrolimus (ATC code: L04AD02) dosage form: RET" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "morphine (ATC code: N02AA01) dosage form: LOE, LSE" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The present announcement serves to conclude agreements on the active ingredient "Amlodipine, Hydrochlorothiazide, Olmesartan (ATC Code: C09DX03)" with pharmaceutical companies within the meaning of Section 130a, Paragraph 8, Clause 1 of the Social Code, fifth book (SGB V) (discount agreements). According to Section 130a, Paragraph 8, Clause 1 of Book V of the Social Code, the invitation to participate is only directed at pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4, Paragraph 18 of the German Medicines Act (AMG) the request to conclude / join discount contracts with non-negotiable conditions for all participants, including the amount of the discount. The corresponding information under IV.1.1) is only due to the systematics of this form. Contractual partners can have an unlimited number of pharmaceutical entrepreneurs or employee associations pharmaceutical company within the meaning of Section 4 Paragraph 18 of the Medicines Act (AMG). The information under II.2.5) is due to the systematics of this publication form. The conclusion of a contract or joining takes place by either completing the required self-declarations or evidence as well as the contract or contracts:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Beclometasone dipropionate, formoterol hemifumarate (ATC code: R03AK08) dosage form: DOS" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active substance "Beclometasone dipropionate, formoterol hemifumarate (ATC code: R03AK08) dosage form: IHP" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Beclometasone dipropionate, formoterol hemifumarate (ATC code: R03AK08) dosage form: INH" with pharmaceutical companies within the meaning of § 130a Abs. 8 Satz 1 Sozialgesetzbuch, fünftes Buch (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.

The purpose of this announcement is to conclude agreements on the active substance "brinzolamide, timolol (ATC code: S01ED51) pharmaceutical form: ATR" with pharmaceutical companies within the meaning of § 130a (8) sentence 1 of the Social Code, Book V (SGB V) (discount agreements). According to § 130a sec. 8 sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 sec. 18 of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount agreements with non-negotiable conditions fixed for all participants, including the amount of the discount. The corresponding indication in point IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz (AMG) can become contractual partners. The information in point II.2.5) is due to the scheme of this publication form. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) With a qualified electronic signature (§ 126a BGB) provided by e-mail to openhouse.rabattvertrag2023-02@kbs.de to KBS.

The earliest start of the contract is 01.02.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.01.2023 at the latest. The beginning of the contract is therefore the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by KBS, provided that the receipt takes place by the 5th of each month; otherwise the 1st of the month after next. Contracts shall terminate automatically, without the need for termination, as soon as contractual partners for the active substance(s) or combination of active substances have been identified through a formal procurement procedure. The deadline for the receipt of accessions is 05.12.2024. In any case, the contracts end on 31.01.2025.